Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 10;9:2341. doi: 10.3389/fimmu.2018.02341

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Yin, Liu, Wang, Ma, Lei, Zhang, Fu, Fu, Hu, Ding, Han, Xu, Shang and Jiang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Blocking TIGIT can restore the function of NK cells in HIV-infected individuals. (A) A representative flow cytometry plot showing the proportion of IFN-γ producing NK cells after treatment with 5 μg/mL anti-human TIGIT antibodies or purified mouse IgG (as a negative control) from HIV-infected individuals. The expression of IFN-γ was gated according to an isotype control. (B) Paired comparisons of the proportions of IFN-γ producing NK cells after treatment with 5 μg/mL anti-human TIGIT antibodies or purified mouse IgG (as a negative control) from HIV-infected individuals (n = 8). (C) Paired comparisons of the proportion of CD107a expressed by NK cells after treatment with 5 μg/mL anti-human TIGIT antibodies or purified mouse IgG (as a negative control) from HIV-infected individuals (n = 7). (D) A representative flow cytometry plot demonstrating the effects of different doses of rTIGIT (0 (medium only), 20, 50, and 100 ng/mL) on IFN-γ and CD107a production by NK cells. (E) Proportion of IFN-γ⁺ NK cells from HIV-infected individuals after treatment with different concentrations of rTIGIT (0, 20, 50, and 100 ng/mL; n = 3). (F) Proportion of CD107a⁺ NK cells from HIV-infected individuals after treatment with different concentrations of rTIGIT (0, 20, 50, and 100 ng/mL; n = 3). (G) Paired comparisons of the proportion of IFN-γ producing NK cells after treatment with 50 ng/mL rTIGIT or rIgG from HIV-infected individuals (n = 7). (H) Paired comparisons of the proportion of CD107a-expressing NK cells after treatment with 50 ng/mL rTIGIT or rIgG from HIV-infected individuals (n = 7). Wilcoxon matched-pairs signed-rank tests were used for comparisons between paired groups. p < 0.05 was considered significant.